Stocks Health care ORMP
NASDAQ · Health careOramed Pharmaceuticals Inc. (ORMP)
In fiscal 2025 capital spending exceeded operating cash flow by $9.2M. At June 30, 2026 it held $15.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Oramed Pharmaceuticals Inc. does
Oramed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORMP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2M | $64.1M | $1.50 | -$9.2M |
| 2024 | n/a | -$19.1M | -$0.48 | -$8.4M |
| 2023 | $1.3M | $5.1M | $0.14 | -$10.5M |
| 2022 | $2.7M | -$36.6M | -$0.94 | -$28.4M |
| 2021 | $2.7M | -$23M | $0.78 | -$21.6M |
| 2020 | $2.7M | -$11.5M | $0.56 | -$12.5M |
Where ORMP ranks in Health care
Dividends
Oramed Pharmaceuticals Inc. paid $0.25 per share in fiscal 2025. At the current price that is a yield of 5.29%.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $0.25 | n/a | n/a |
Latest SEC filings
What Oramed Pharmaceuticals Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- August 3, 2026Additional proxy material DEFA14A
- August 3, 2026Proxy statement DEF 14A
- June 30, 2026
- June 29, 2026Passive stake changed SCHEDULE 13G/A
- May 19, 2026Quarterly report 10-Q · period to March 31, 2026
- May 15, 2026Late quarterly report notice NT 10-Q
Insider trades
What the people running Oramed Pharmaceuticals Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 7 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 24, 2026 | Gabay AvrahamChief Financial Officer | Received as pay | 209,291 | - |
| September 24, 2026 | Kidron MiriamChief Scientific Officer, Director | Received as pay | 208,125 | - |
| September 24, 2026 | Kidron MiriamChief Scientific Officer, Director | Received as pay | 209,291 | - |
| September 24, 2026 | Hexter JoshuaCOO & CBO | Received as pay | 75,455 | - |
| September 24, 2026 | Hexter JoshuaCOO & CBO | Received as pay | 209,291 | - |
| September 24, 2026 | Kidron NadavPresident and CEO, Director | Received as pay | 349,497 | - |
| September 24, 2026 | Kidron NadavPresident and CEO, Director | Received as pay | 368,765 | - |
Questions about ORMP
What does Oramed Pharmaceuticals Inc. do?
Oramed Pharmaceuticals Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ORMP.
Is Oramed Pharmaceuticals Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $174.9M.
When did Oramed Pharmaceuticals Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
Similar companies
Compare ORMP with
Follow ORMP
Get an email when Oramed Pharmaceuticals Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ORMP: get an email when it filesWhere the numbers come from
Financial figures are the values Oramed Pharmaceuticals Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.